CD8A and colorectal carcinoma: However, before such tests can be implemented in clinical practice, they must comply with strict clinical laboratory standards and undergo clinical validation, ideally through prospective trials.17-20 Only Immunoscore, a semiautomated platform that quantifies CD3+ and CD8+ T cells in tissue sections, has met these requirements for immune markers.21-24 Immunoscore provides prognostic information that traditional diagnostic and staging criteria do not capture for patients with colorectal carcinoma (CRC), serving as a complement to the conventional TNM staging system.